GLP-1 类似物 comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-07-04. Where a claim depends on a specific study, the study is described rather than over-claimed.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
该分子作为 GLP-1 受体的选择性激动剂发挥作用，受体属于 B 类 G 蛋白偶联受体家族，激活后经 Gs 通路提升细胞内环腺苷酸水平。在胰腺 β 细胞，信号促进葡萄糖依赖性的胰岛素释放，血糖偏低时该作用明显减弱。在胰岛 α 细胞，胰高血糖素分泌受到抑制。中枢神经系统与胃肠道同样存在受体表达，相应信号参与食欲调节以及胃排空速率的降低。
皮下注射后吸收相对缓慢，绝对生物利用度约为百分之八十九，血药浓度峰值通常出现在给药后一到三天。与白蛋白结合使清除减慢，终末半衰期约为一百六十五小时，接近一周。连续给药约四到五周后达到稳态暴露水平。表观分布容积约为每千克零点二五升，血浆蛋白结合率超过百分之九十九。代谢以蛋白水解切割和脂肪二酸侧链的 β-氧化为主，相关产物主要经尿液与粪便排出。
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | free base, without counter-ion |
| Molecular weight | About 4114 Da | peptide backbone plus attached lipid chain |
| Plasma half-life | About 165 hours | supports once-weekly dosing in humans |
| Plasma protein binding | Greater than 99 percent | attributed mainly to serum albumin |
| Receptor target | GLP-1 receptor | Gs-coupled, raises intracellular cyclic AMP |
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1, a hormone released from intestinal L cells after food intake. The molecule is a 31-amino-acid backbone modified at three positions to resist cleavage by dipeptidyl peptidase-4, the enzyme that degrades native GLP-1 within minutes. A lysine residue at position 26 carries a linker and a C18 fatty diacid, which promotes binding to serum albumin and slows renal clearance. These changes extend the circulating half-life from roughly two minutes to about one week in humans.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Receptor binding triggers G protein signaling that raises intracellular cyclic AMP in pancreatic beta cells. Insulin release follows in a glucose-dependent manner, so secretion increases when blood glucose is elevated and diminishes when it is not. The same signaling suppresses glucagon release from alpha cells and slows gastric emptying, which blunts the post-meal glucose rise. In the brain, receptor activation in regions such as the arcuate nucleus is associated with reduced appetite and lower energy intake. How much each of these effects contributes to overall weight change is not fully settled.
Two structural features account for the prolonged half-life of semaglutide. A modified amino acid at position 8 resists cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GLP-1. A fatty diacid side chain binds serum albumin, which limits renal clearance and protects the peptide from enzymatic breakdown. These modifications yield a plasma half-life of approximately one week in humans, allowing once-weekly administration. The relationship between plasma concentration and clinical effect varies between individuals, and sources of that variability are still being characterized.
Semaglutide is a synthetic peptide analog of glucagon-like peptide-1 (GLP-1), a hormone released from intestinal L-cells after food intake. The compound belongs to the incretin mimetic class and acts at GLP-1 receptors distributed across pancreatic, gastrointestinal, cardiovascular, and central nervous system tissues. Compared with native GLP-1, the molecule carries structural changes that extend its activity from minutes to roughly one week. It is studied for glycemic control in type 2 diabetes and for weight management, and its effects on cardiovascular and other outcomes remain active research areas.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
The original liquid formulation without EDTA was returned to the market in the US in May 2008. In 2009, Genzyme acquired the rights to Leukine from Bayer, including the manufacturing facility in the Seattle area. In March 2018 the label was extended to use as a countermeasure for acute radiation syndrome. In February 2018, Partner Therapeutics, Inc. acquired the global rights to develop, manufacture, and commercialize Leukine (sargramostim) from Sanofi.
This converts IDL into low-density lipoprotein (LDL), which is taken up by cells that require cholesterol for incorporation into their cell membranes or for synthetic purposes (e.g. the formation of the steroid hormones). The remainder of the LDLs is removed by the liver. Adipose tissue and lactating mammary glands also take up glucose from the blood for conversion into triglycerides. This occurs in the same way as in the liver, except that these tissues do not release the triglycerides thus produced as VLDL into the blood. Adipose tissue cells store the triglycerides in their fat droplets, ultimately to release them again as free fatty acids and glycerol into the blood (as described above), when the plasma concentration of insulin is low, and that of glucagon and/or epinephrine is high. Mammary glands discharge the fat (as cream fat droplets) into the milk that they produce under the influence of the anterior pituitary hormone prolactin. All cells in the body need to manufacture and maintain their membranes and the membranes of their organelles. Whether they rely entirely on free fatty acids absorbed from the blood, or are able to synthesize their own fatty acids from blood glucose, is not known. The cells of the central nervous system will almost certainly have the capability of manufacturing their own fatty acids, as these molecules cannot reach them through the blood–brain barrier.
Kimon Georgiev established the political circle "Zveno" with Damyan Velchev in 1927, firstly as a non-partisan organization that aims to improve the socio-political climate in the country. It proclaimed its support for authoritarian power, raised above the strictly party interests, with national purpose. The fascists influence on the Zveno is undisputed, but its not characterized as fascist, but a corporate statism in which it mainly drew inspiration from Italian fascism. Georgiev ceased ties with the Democratic Alliance in 1930 and after the 1931 Bulgarian parliamentary election, he was no longer a deputy of his group. He became a leader of the Zveno and in the beginning of 1932, a newspaper Izgrev was published with one of the editors being Georgiev himself. He published articles in which he criticized communism and the Soviet Union, as well as declaring for a strong government "in the name of order and state intervention in economic life." The primary component of Zveno's ideology was anti-communism, which embraced strong "supra-party" authoritarian bourgeois power of the fascist variety while rejecting the bourgeois democratic system of governance. The bulk of Zveno members joined Aleksander Tsankov's Popular Social Movement in January 1934, but a smaller group led by Kimon Georgiev kept the group operating independently. Zveno was a little organization with little social interaction. It made touch with the Military League, which was once more planning a violent change of government.
== Contributions == De made significant contributions to the recent understanding of cholera and related diarrhoeal diseases and set a permanent milestone in the modern view of diseases caused by bacterial exotoxins. Followed by the discovery of Vibrio cholerae in 1884 by Robert Koch, many works have been carried out all over the world to answer many questions related with its pathogenesis and mode of transmission in causing outbreaks. The seminal works of De in Calcutta (now Kolkata) during 1950–60 breached several qualms pertaining to the enteric toxin produced by bacteria including V. cholerae and Escherichia coli. Three of his works viz., ligated intestinal loop method (which was a reinvention of Violle and Crendiropoulo method in 1915, but De was unaware of this work and made an independent discovery) for studying cholera in rabbit model; ileal loop model to demonstrate the association of some strains of E. coli with diarrhoea and lastly but most importantly is his discovery of cholera toxin in 1959 in the cell-free culture filtrate of V. cholerae that stimulated a specific cellular response. As noted by Garfield in his 1986 tribute, De was the first to demonstrate that cholera bacteria secrete enterotoxin. This discovery eventually promoted research to find a treatment aimed directly at neutralising the cholera enterotoxin. De's paper "Enterotoxicity of bacteria-free culture-filtrate of Vibrio cholerae," while initially unrecognised, today is considered a milestone in the history of cholera research. Biochemist W. E.
The first king of Hungary, Stephen I, who supported Western European missionaries, defeated the local chieftains and established Roman Catholic bishoprics (office of a bishop) in Transylvania and Banat in the early 11th century. Significant Pecheneg groups fled to the Byzantine Empire in the 1040s; the Oghuz Turks followed them, and the nomadic Cumans became the dominant power of the steppes in the 1060s. Cooperation between the Cumans and the Vlachs against the Byzantine Empire is well documented from the end of the 11th century. Scholars who reject the Daco-Roman continuity theory say that the first Vlach groups left their Balkan homeland for the mountain pastures of the eastern and southern Carpathians in the 11th century, establishing the Romanians' presence in the lands to the north of the Lower Danube.
Sources: en.wikipedia.org
The earliest known description of the disease was in 1841 by the American physician Charles Oscar Waters. The condition was described in further detail in 1872 by the American physician George Huntington. The genetic basis was discovered in 1993 by an international collaborative effort led by the Hereditary Disease Foundation. Research and support organizations began forming in the late 1960s to increase public awareness, provide support for the afflicted and their families, and promote research. Research directions include determining the exact mechanism of the disease, improving animal models to aid with research, testing of medications and their delivery to treat symptoms or slow the progression of the disease, and studying procedures such as stem-cell therapy with the goal of replacing damaged or lost neurons.
== Causes == A spontaneous spinal CSF leak refers to any CSF leak that has not been preceded by a surgical or other medical procedure. Later evidence suggests that these leaks result from either a discogenic pathology, such as microspur, osteophyte or spinal disc herniation that pierces the dura like a knife, connective tissue disorder (which can often lead to discogenic pathology), or spinal drainage problems. A cerebrospinal fluid leak can be a rare complication of an anterior cervical discectomy and fusion. One study suggested a CSF leak to follow from 0.5% of operations. Another study suggests a CSF leak to follow from 1% of operations. In most of these cases repair is successful.
=== Dependence and withdrawal === Long-term use of high doses of tramadol causes physical dependence and withdrawal syndrome. These include both symptoms typical of opioid withdrawal and those associated with serotonin–norepinephrine reuptake inhibitor (SNRI) withdrawal; symptoms include numbness, tingling, paresthesia, and tinnitus. Psychiatric symptoms may include hallucinations, paranoia, extreme anxiety, panic attacks, and confusion. In most cases, tramadol withdrawal will set in 12–20 hours after the last dose, but this can vary. Tramadol withdrawal typically lasts longer than that of other opioids. Seven days or more of acute withdrawal symptoms can occur as opposed to typically 3 or 4 days for other codeine analogs.
Fodé Sylla - former member of the European parliament, former president of SOS Racisme Hamidou Diallo- American professional basketball player for the Oklahoma City Thunder of the National Basketball Association (NBA) Ira Frederick Aldridge – stage actor, claims to have descended from the Fulani princely line, USA Omar Ibn Said (c. 1770 – 1864) – Islamic scholar from Futa-Toro. Taken as a slave to Charleston, South Carolina in 1807. Escaped to North Carolina, Wrote a slave narrative in Arabic professing his Islamic faith. Died before end of Civil War. Richard Pierpoint - Slave, freed slave, British Army soldier and farmer in Fergus, Ontario Canada. Yarrow Mamout (or Mahmoud or Mamood or Muhammad Yaro) – was a former slave, entrepreneur, and property owner in Georgetown, Washington, DC, USA
== Clinicians == Physician Bachelor of Medicine, Bachelor of Surgery (MBBS) Doctor of Medicine (M.D.) Doctor of Osteopathic Medicine (D.O.) Dentist Bachelor of Dental Surgery (BDS) Doctor of Dental Medicine (DMD) Doctor of Dental Surgery (DDS) Optometrist Doctor of Optometry (OD) Podiatrist Doctor of Podiatry (DPM) Chiropractor Doctor of Chiropractic (DC) Physician Assistant (PA) Doctor of Medical Science (D.Med.Sc.), (D.M.Sc.) Master of Medical Science (M.Med.Sc), (M.M.Sc.) Master of Physician Assistant Studies (M.P.A.S.) Professional (Second-entry) Bachelor of Science in Physician Assistant (B.Sc.PA.), (B.H.Sc.PA) Pharmacist (R.Ph.) Doctor of Pharmacy (PharmD) Master of Pharmacy (MPharm) Bachelor of Pharmacy (B.Pharm)
Sources: en.wikipedia.org
The researcher will select a subset of the 'virtual library' for actual synthesis, based upon various calculations and criteria (see ADME, computational chemistry, and QSAR). In 1996, at Parke-Davis Pharmaceutical Research, scientist Anthony Czarnik directed research into and reported the first use of automation in synthesizing compound libraries. As the founding editor of the American Chemical Society's Journal of Combinatorial Chemistry, he also led research into RFID tags for targeted sorting in compound library synthesis.
Tyrannosaurus lived during what is referred to as the Lancian faunal stage (Maastrichtian age) at the end of the Late Cretaceous. Tyrannosaurus ranged from Canada in the north to at least New Mexico in the south of Laramidia. Several notable Tyrannosaurus remains have been found in the Hell Creek Formation. During the Maastrichtian this area was maritime to subtropical, with a warm and humid climate. The flora consisted mostly of angiosperms, but also included trees like dawn redwood (Metasequoia). Archosaurs discovered from this formation include the ceratopsians Leptoceratops, Torosaurus, and Triceratops, the hadrosaurid Edmontosaurus annectens, the parksosaurid Thescelosaurus, the ankylosaurs Ankylosaurus and Denversaurus, the pachycephalosaurs Pachycephalosaurus, Platytholus and Sphaerotholus, the paravian theropods Acheroraptor and Pectinodon, other maniraptoran theropods Anzu, Eoneophron, Trierarchuncus and indeterminate ornithomimids, the tyrannosauroid Nanotyrannus, and the azhdarchid pterosaur Infernodrakon.
ATP + H2O + oligopeptide [oligopeptide - binding protein][side 1] = ADP + phosphate + oligopeptide [side 2] + [oligopeptide - binding protein][side 1] 7.4.2.7 ABC-type alpha-factor-pheromone transporter The enzyme appears in viruses and cellular organisms characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. Does not undergo phosphorylation during the transport process. A yeast enzyme that exports the α-factor sex pheromone. ATP + H2O + alpha factor [side 1] = ADP + phosphate + alpha factor [side 2] 7.4.2.8 ABC-type protein-secreting ATPase The expected taxonomic range for this enzyme is: Archaea, Bacteria. A non-phosphorylated, non-ABC (ATP-binding cassette) ATPase that is involved in protein transport. ATP + H2O + cellular protein [side 1] = ADP + phosphate + cellular protein [side 2] 7.4.2.9 ABC-type dipeptide transporter The enzyme appears in viruses and cellular organisms. ATP-binding cassette (ABC) type transporter, characterized by the presence of two similar ATP-binding domains/proteins and two integral membrane domains/proteins. A bacterial enzyme that interacts with an extracytoplasmic substrate binding protein and mediates the uptake of dipeptides and tripeptides.
Assassinian Jingi (アサシン星人ジンギ, Asashin Seijin Jingi): A self-centered scorpion-themed assassin from Planet Assassin who has a chain on his head capable of sending targets to another dimension and who considers his skills far beyond that of typical killers, becoming murderously violent whenever someone questions or insults him. He kills indiscriminately until the Dekarangers confront him. He pilots a Kaijuki called Ultimate Evil 2 (アルティメットイビル2, Arutimetto Ibiru Tsū) in retaliation, but is deleted by the Deka Wing Cannon. Jingi is voiced by Minami Takayama (高山 みなみ, Takayama Minami). Sumasuleenian Nikaradar (スマスリーナ星人ニカレーダ, Sumasurīna Seijin Nikarēda): A spiky squid-themed criminal, and breeder of alien monsters called Browgoul, from Planet Sumasuleen who is capable of disguising himself as others and is willing to sacrifice countless worlds to ensure his pets' existence. After arriving on Earth, he murdered a professor and fed his corpse to a hatched Browgoul before assuming the deceased's identity to redirect a meteor towards Earth. However, the Dekarangers discover his true identity and delete him via their S.W.A.T. Modes. Nikaradar is voiced by Hiroyuki Shibamoto (柴本 浩行, Shibamoto Hiroyuki). Bokudenian Biskes (ボクデン星人ビスケス, Bokuden Seijin Bisukesu): A reckless fish-themed criminal and former friend of Kruger's from Planet Bokuden who previously trained with him, is charged with illegally challenging 999 fighters in duels to the death, and possesses the Sword Altair (ソード・アルタイル, Sōdo Arutairu), with which he can perform the Altair Slash (アルタイルスラッシュ, Arutairu Surasshu) attack.
Sources: en.wikipedia.org
Native GLP-1 is a short-lived peptide cleared within one to two minutes by dipeptidyl peptidase-4 and related enzymes. Semaglutide keeps the receptor-binding backbone but adds substitutions and a lipid chain. These changes block the main cleavage site and allow reversible albumin binding, extending the half-life to roughly 165 hours.
Albumin is the most abundant protein in plasma and carries molecules that bear fatty-acid chains. Binding shields the peptide from renal filtration and from peptidases, keeping a circulating reservoir. Slow release from this reservoir produces sustained receptor occupancy and supports infrequent dosing.
The insulinotropic effect is glucose-dependent, meaning secretion increases mainly when glucose is elevated. This property is often described as lowering the chance of hypoglycaemia when the compound is used alone. Other glucose-lowering agents used at the same time can still cause low blood glucose.
差别集中在三处：第 8 位残基被非天然氨基酸取代，第 34 位换成精氨酸，第 26 位增加一条脂肪酸侧链。前两处改动降低酶解速率，侧链则通过白蛋白结合延长循环时间。综合结果是半衰期从约两分钟延长到约一周。